Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

N/ATerminatedNCT03319914

Hope Pharmaceuticals5 enrolled

Overview

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study. In this ST-003 (OF-CALISTA) study, the occurrence of delayed adverse events, standard of care treatments for calciphylaxis (medications \[including Sodium Thiosulfate Injection and pain medication\], wound debridement, amputation, hyperbaric oxygen therapy, and surgical parathyroidectomy), and calciphylaxis-related complications (new or worsening skin lesions, ulceration, infection, sepsis and hospitalizations) will be recorded during an 8-week observation period following patient participation in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Calciphylaxis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previously enrolled as a patient in ST-001 CALISTA study * Willing to provide written informed consent * Willing and able to adhere to all study-related procedures * Willing to authorize release of medical records * Willing to authorize collection of medical data from health care providers * Provide email, home address and phone number where he/she can be reached Exclusion Criteria: • Patient did not participate in ST-001 CALISTA study

Locations (3)

Massachusetts General Hospital

Boston, Massachusetts, United States

Veterans Administration Medical Center

Albany, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

Outcomes

Primary Outcomes

Observation of delayed adverse events, standard of care treatments for calciphylaxis following participation in ST-001

Record the occurrence of delayed adverse events, standard of care treatments for calciphylaxis(medications \[including Sodium Thiosulfate Injection and pain medication\], wound debridement, amputation, hyperbaric oxygen therapy, and surgical parathyroidectomy), and calciphylaxis-related complications (new or worsening skin lesions, ulceration, infection, sepsis and hospitalizations) following participation in ST-001

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.